New virus therapy tested for Tough-to-Treat ovarian cancer
NCT ID NCT07211659
Summary
This is an early safety study testing a new treatment called THEO-260 for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The main goal is to find a safe dose and see what side effects occur. Participants will receive six doses of the treatment directly into their abdomen over two weeks, followed by regular check-ups to monitor their health and see if the treatment shows any signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.